IN Brief:
- The first batch is due to be presented at Fi Europe in Frankfurt on 17 November.
- Potential applications include cheese, yoghurt, butter and hybrid dairy formulations.
- Opalia remains at laboratory-scale validation, with regulatory and scaling hurdles ahead.
Hoogwegt is preparing to purchase its first batch of cell-cultured whole milk from Canadian food technology company Opalia for composition testing and dairy product development. The Netherlands-based ingredients group plans to examine whether the material can be used in products such as fresh cheese, yoghurt and butter, including possible combinations with conventional milk. The partners expect to present a prototype at Fi Europe in Frankfurt on 17 November, with the first material delivery intended as an evaluation step rather than a commercial market launch.
The underlying approach differs from precision fermentation, which can use microorganisms to manufacture selected milk proteins. Opalia is developing milk produced from bovine mammary cells, attempting to generate a more complete milk material rather than one isolated protein ingredient. The resulting composition is central to whether traditional dairy processing operations can use it. Manufacturing cheese or yoghurt depends on the behaviour of proteins and other constituents under heat, acidification, enzyme treatment and fermentation, not simply whether an ingredient tastes milky.
Hoogwegt’s planned evaluations will examine both composition and functionality in dairy processing. The distribution of proteins and fats may affect coagulation, emulsion stability and mouthfeel, while yoghurt manufacture relies on interactions between the milk substrate and starter cultures during incubation and storage. Fresh cheese, yoghurt and butter impose different process conditions, so successful trials in one application would not establish suitability for every dairy product. The results should help identify which manufacturing routes, if any, warrant more extensive development.
Opalia says its production process has been validated at laboratory scale, with industrial production and regulatory authorisation still ahead. The first delivery’s volume and agreed price have not been disclosed. Hoogwegt global technology director Roland Wientjes has said the initial price reflects the cost of producing experimental material, rather than an established commercial margin. A purchase at this stage can supply material for controlled evaluation without demonstrating competitive production costs, consistent output or market-ready capacity.
Cell cultivation involves maintaining specialised cells in a controlled growth environment and recovering material that can meet food standards. Beyond biological output, industrial scale-up would require consistent upstream media supply, contamination control, process monitoring and reproducible recovery of the intended composition. The suitability of a process at laboratory scale cannot be assumed at much larger volumes, where equipment geometry, mass transfer, cleaning systems and batch-to-batch variability may become more difficult to manage. These are relevant engineering tests for any proposed manufacturing expansion.
The two companies have an established relationship rather than a newly signed supply partnership. Hoogwegt has invested in Opalia since 2023 and entered a two-year development agreement in 2025, according to reporting based on comments from the partners. The November handover is a specific milestone under that programme: material made available to Hoogwegt for tests in dairy formulations. Neither company has identified a customer launch, a production-site investment decision or a contract for the supply of consumer-ready cell-cultured milk.
Regulation will determine the pace of any market entry. Opalia is targeting a North American regulatory application within the coming year and is working towards food-grade status in 2028. These are company ambitions, not approvals or guaranteed dates. Authorisation requirements also differ between jurisdictions, and an approval in one market would not by itself establish legal status in the United Kingdom or European Union. Food manufacturers considering future projects would need ingredient identity, safety evidence, specifications and labelling positions long before placing products on shelves.
The project also illustrates the difference between ingredient innovation and factory implementation. Conventional dairy plants depend on large, predictable flows of milk with well-characterised properties, supported by established hygiene regimes and cold chains. A novel milk material would have to meet those operating requirements or be directed towards more specialised product categories where smaller batches are commercially feasible. Testing its protein, fat and processing performance is therefore a necessary first step, but does not resolve industrial scaling or sourcing questions.
Different dairy applications should provide distinct measures of functionality once the evaluation material becomes available. Yoghurt trials can assess protein behaviour during heat treatment, acidification and chilled storage, while butter trials depend on how the material’s fat phase separates and crystallises under processing. Even if a sample performs in one formulation, manufacturers will need to establish repeatability, microbiological controls and raw-material specifications before transferring the process to larger equipment. Those questions are still open because the reported technology remains at laboratory scale.
The partners plan to present a prototype and hand over the first batch at Fi Europe in Frankfurt on 17 November 2026. Composition testing and the subsequent dairy trials should establish which products offer a credible next development step; regulatory approval and industrial capacity will still be required before consumer supply can begin.
